Related Experiment Video
Updated: Jun 21, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Anti-hyperglycaemic potential of Psidium guajava raw fruit peel
Prashant K Rai1, Dolly Jaiswal, Shikha Mehta
1Drug Development Division, Department of Chemistry, University of Allahabad, Allahabad, India.
Background & Objective:
This study was undertaken to evaluate the glycaemic potential of aqueous extract of Psidium guajava unripe fruit peel on blood glucose level (BGL) of normal and streptozotocin induced mild and severely diabetic rats as an extension of our previous work carried out on Psidium guajava ripe fruit peel.
Methods:
The aqueous extract of P. guajava unripe fruits was prepared. Male 6-8 wk old albino Wistar rats were selected for the experiments. Diabetes was induced by streptozotocin infection. Blood glucose levels were measured by glucose oxidase method. Antihyperglycaemic activity of the extract was assessed in mild and severely diabetic rats.
Results:
The maximum fall of 21.2 per cent (P<0.01) and 26.9 per cent (P<0.01) after 3 h of glucose administration during glucose tolerance test (GTT) was observed in BGL from a dose of 400 mg/kg, identified as the most effective dose, in normal and mild diabetic rats respectively. In severely diabetic rats the maximum fall of 20.8 and 17.5 per cent in fasting blood glucose (FBG) and post prandial glucose (PPG) levels, and 50 per cent (P<0.01) in urine sugar levels was observed with the same dose. Haemoglobin level increased by 5.2 per cent (P<0.05) and body weight by 2.5 per cent (P<0.05) after 21 days treatment.
Interpretation & Conclusion:
Normal, mild and severely diabetic rat models had shown hypoglycaemic as well as antidiabetic effect of the unripe guava fruit peel aqueous extract. Further studies need to be done to characterize the active components of the peel.
Related Concept Videos
Hyperglycemia
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes I: Introduction
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon
